Strategic Research Institute will be organizing "Inflammatory Processes in Drug Discovery Conference & Exposition, " for the world inflammatory disease drug discovery research community in Philadelphia, PA.

Drug discovery and development for safer and more effective therapies for RA is based upon an improved understanding of the many inflammatory mediators that contribute to the pathogenesis of the disease, in which this understanding of common inflammatory processes casts the net wider for utility of new drugs and novel therapies and an increasing number of indications. This conference will review many drug discovery programs, which will provide the next generation of drugs that target common processes in inflammatory disease.

Some of the participants include 3M Pharmaceuticals, Abbott Laboratories, AstraZeneca, Astex Technology Ltd., Atherogenics Inc., Aventis Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene San Diego, Merck Research Laboratories, Meyer Pharmaceuticals, Molecular Staging, Pfizer Global R&D Groton Laboratories, Rigel Inc., Roche Pharmaceuticals, Vertex Pharmaceuticals, Albert Einstein College of Medicine & University of North Carolina.

The keynote addresses will be
Cytokine Profiling in Inflammatory Diseases -- Dhaval D. Patel, University Of North Carolina
Using Inflammation Mediators to Quantify Drug Effects During Clinical Trials -- Stephen Kingsmore, Molecular Staging
Bulking up Drug Discovery: The Humanisation Process -- Martin Braddock, AstraZeneca

Exposition participants from this series includes: Bayer Corporation, Igen International Inc., Isis Research, Source Precision Medicine, Upstate Inc., RDL Inc. & Lifespan Biosciences.